catabolic disease

A condition characterised by rapid weight loss and loss of fat and skeletal muscle mass, which may occur in a background of either an acute, self-limited disease—e.g., injury, infection—or a chronic condition—e.g.,diabetic ketoacidosis, multisystem organ failure, AIDS, advanced cancer, chemotherapy, radiation therapy
Associated clinical events Immunosuppression, muscle weakness, predisposition to pulmonary embolism, thrombophlebitis, altered stress response
Management Aggressive nutritional support in catabolic diseases may not prevent protein loss; specialised nutrition—e.g., glutamine, arginine, branched-chain amino acids, n-3 (omega-3) fatty acids, growth hormone, possibly IGF-I and EGF—may decrease protein loss, hospitalisation

catabolic disease

Catabolic illness Metabolic disease A condition characterized by rapid weight loss and loss of fat and skeletal muscle mass, which may occur in a background of either an acute, self-limited disease–eg, injury, infection or a chronic condition–eg DKA, multisystem organ failure, AIDS, advanced CA, chemotherapy, RT Associated clinical events Immunosuppression, muscle weakness, predisposition to PTE, thrombophlebitis, altered stress response Management Aggressive nutritional support in CI may not prevent protein loss; specialized nutrition–eg, glutamine, arginine, branched-chain amino acids, n-3–omega-3 fatty acids, growth hormone, possibly IGF-I and EGF, may ↓ protein loss, hospitalization
References in periodicals archive ?
Inflammatory conditions such as mediators of sepsis increase the catabolic disease state.
Parenteral nutrition is generally reserved for the acutely ill or injured hospitalized patient who has unsuccessfully attempted enteral feeding and presents with catabolic disease and a nonfunctioning GI tract (Demling & DeSanti, 2000).
Whereas Celtrix already owns specific intellectual property relating to the systemic treatment of osteoporosis, catabolic diseases, wound healing, trauma, burns, as well as certain hematologic and renal indications, this new patent claims the use of SomatoKine to deliver IGF-I at dose levels that the company believes are necessary for efficacy.